Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCY-635 + SOC in Genotype 1 Hepatitis C
NCT01265511Phase 2Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Nov 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C (HCV) comparing Placebo with SCY-635 600 mg (2 arms). Primary endpoint: Proportion of subjects with an undetectable serum HCV RNA level at 4 weeks. Started Nov 2010; status: completed.
02
Drugs
SCY-635
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01265511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01265511.